Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
Ju Won KimKyungmin LeeJi Yoon LeeSook Ryun ParkYu Jung KimIn Gyu HwangWoo Kyun BaeJae Ho ByunJung Sun KimEun Joo KangJeeyun LeeSang Joon ShinWon Jin ChangEun-Ok KimJason K SaKyong-Hwa ParkPublished in: Journal for immunotherapy of cancer (2024)
NCT04761744.